Leqvio

Inclisiran, the active ingredient in Leqvio, is a siRNA therapeutic presented as a subcutaneous injection for subcutaneous use. It lowers LDL‑cholesterol in adults with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or mixed dyslipidemia, typically as an adjunct to diet and statin therapy.

GNH USA supplies Leqvio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leqvio is a lipid‑lowering agent that targets elevated LDL‑cholesterol across several dyslipidemic conditions.

Primary hypercholesterolemia: reduces LDL‑cholesterol levels when added to diet and statin therapy. Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction in genetically predisposed patients. Mixed dyslipidemia: improves overall lipid profile as part of a comprehensive cardiovascular risk‑reduction strategy.

Leqvio is generally well tolerated, but adverse reactions have been reported.

Common Side Effects: - Injection site pain or erythema. - Mild headache. - Upper respiratory tract infection symptoms. - Transient increase in liver enzymes. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema). - Persistent injection site reactions (abscess, cellulitis). - Significant hepatic injury. - Unexplained hypotension. - Immune-mediated thrombocytopenia.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for potential risks.

Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. Renal impairment: assess renal function; dose adjustment may be required. Hepatic disease: monitor liver enzymes regularly. Concomitant statin therapy: watch for additive muscle-related symptoms. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Inclisiran may interact with other agents that affect lipid metabolism or immune response.

Major Interactions (Avoid): - Concurrent use of strong PCSK9‑targeting monoclonal antibodies (may lead to excessive LDL‑cholesterol lowering). - Live vaccines administered within 4 weeks of injection (potentially reduced vaccine efficacy).

Moderate Interactions (Monitor Closely): - Statins (monitor for muscle toxicity). - CYP‑modulating drugs (although inclisiran is not metabolized by CYP enzymes, monitor overall lipid‑lowering effect). - Anticoagulants (watch for bleeding if severe injection site reactions occur).